PL450241A1 - Pozytywny allosteryczny modulator (PAM) transportera EAAT2/GLT-1 glutaminianu do stosowania w leczeniu lub zapobieganiu świądu - Google Patents

Pozytywny allosteryczny modulator (PAM) transportera EAAT2/GLT-1 glutaminianu do stosowania w leczeniu lub zapobieganiu świądu

Info

Publication number
PL450241A1
PL450241A1 PL450241A PL45024124A PL450241A1 PL 450241 A1 PL450241 A1 PL 450241A1 PL 450241 A PL450241 A PL 450241A PL 45024124 A PL45024124 A PL 45024124A PL 450241 A1 PL450241 A1 PL 450241A1
Authority
PL
Poland
Prior art keywords
pruritus
prevention
treatment
eaat2
glt
Prior art date
Application number
PL450241A
Other languages
English (en)
Inventor
Krzysztof KAMIŃSKI
Szczepan MOGILSKI
Michał ABRAM
Marcin JAKUBIEC
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL450241A priority Critical patent/PL450241A1/pl
Priority to PCT/PL2025/050087 priority patent/WO2026106496A1/en
Publication of PL450241A1 publication Critical patent/PL450241A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Magnetic Treatment Devices (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest pozytywny allosteryczny modulator (PAM) transportera EAAT2/GLT-1 do stosowania w leczeniu lub zapobieganiu świądu, przy czym korzystnie jest to związek o wzorze (I), gdzie: A - oznacza wodór lub deuter, B - oznacza wodór lub deuter, X - oznacza wodór lub deuter lub fluor, Y - oznacza wodór lub deuter, do stosowania w leczeniu lub zapobieganiu świądu, zwłaszcza świądu zależnego i niezależnego od histaminy.
PL450241A 2024-11-12 2024-11-12 Pozytywny allosteryczny modulator (PAM) transportera EAAT2/GLT-1 glutaminianu do stosowania w leczeniu lub zapobieganiu świądu PL450241A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL450241A PL450241A1 (pl) 2024-11-12 2024-11-12 Pozytywny allosteryczny modulator (PAM) transportera EAAT2/GLT-1 glutaminianu do stosowania w leczeniu lub zapobieganiu świądu
PCT/PL2025/050087 WO2026106496A1 (en) 2024-11-12 2025-11-12 Positive allosteric modulator (pam) of the eaat2/glt-1 glutamate transporter for use in the treatment or prevention of pruritus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL450241A PL450241A1 (pl) 2024-11-12 2024-11-12 Pozytywny allosteryczny modulator (PAM) transportera EAAT2/GLT-1 glutaminianu do stosowania w leczeniu lub zapobieganiu świądu

Publications (1)

Publication Number Publication Date
PL450241A1 true PL450241A1 (pl) 2026-05-18

Family

ID=98429932

Family Applications (1)

Application Number Title Priority Date Filing Date
PL450241A PL450241A1 (pl) 2024-11-12 2024-11-12 Pozytywny allosteryczny modulator (PAM) transportera EAAT2/GLT-1 glutaminianu do stosowania w leczeniu lub zapobieganiu świądu

Country Status (2)

Country Link
PL (1) PL450241A1 (pl)
WO (1) WO2026106496A1 (pl)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019226820A1 (en) * 2018-05-22 2019-11-28 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis
PL429656A1 (pl) * 2019-04-16 2020-10-19 Uniwersytet Jagielloński Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych
PL433567A1 (pl) * 2020-04-16 2021-10-18 Uniwersytet Jagielloński Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL244897B1 (pl) * 2021-11-24 2024-03-25 Univ Jagiellonski Deuterowane funkcjonalizowane pochodne α-alaniny, zwłaszcza do leczenia chorób neurologicznych

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019226820A1 (en) * 2018-05-22 2019-11-28 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis
PL429656A1 (pl) * 2019-04-16 2020-10-19 Uniwersytet Jagielloński Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych
PL433567A1 (pl) * 2020-04-16 2021-10-18 Uniwersytet Jagielloński Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAMIŃSKI K. ET AL.: "Bioorganic & Medicinal Chemistry, 2015, 23(10): 2548-2561", DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW HYBRID ANTICONVULSANTS DERIVED FROM N-BENZYL-2-(2,5-DIOXOPYRROLIDIN-1-YL)PROPANAMIDE AND 2-(2,5-DIOXOPYRROLIDIN-1-YL)BUTANAMIDE DERIVATIVES. *
KAMIŃSKI, K. ET AL.: "Neurotherapeutics, 2020, 17: 309-328", N-BENZYL-(2,5-DIOXOPYRROLIDIN-1-YL)PROPANAMIDE (AS-1) WITH HYBRID STRUCTURE AS A CANDIDATE FOR A BROAD-SPECTRUM ANTIEPILEPTIC DRUG. *
RAPACZ, A. ET AL.: "Naunyn-Schmiedeberg's Arch Pharmacol, 2017, 390: 567-579", ANALGESIC, ANTIALLODYNIC, AND ANTICONVULSANT ACTIVITY OF NOVEL HYBRID MOLECULES DERIVED FROM N-BENZYL-2-(2,5-DIOXOPYRROLIDIN-1-YL) PROPANAMIDE AND 2-(2,5-DIOXOPYRROLIDIN-1-YL)BUTANAMIDE IN ANIMAL MODELS OF PAIN AND EPILEPSY. *

Also Published As

Publication number Publication date
WO2026106496A1 (en) 2026-05-21